{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:37:57Z","timestamp":1753889877913,"version":"3.41.2"},"reference-count":38,"publisher":"Becaris Publishing Limited","issue":"1","funder":[{"name":"Genmab US Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            To evaluate trials of systemic therapies in transplant-ineligible or -experienced, relapsed\/refractory diffuse large-B cell lymphoma\u00a0and the impact of patient characteristics on overall response rate (ORR).\n            <jats:bold>Patients &amp; methods:<\/jats:bold>\n            Systematically reviewed multiple databases through 22 July 2021. Analyzed variations in patient characteristics and their relationship with ORR across trials.\n            <jats:bold>Results:<\/jats:bold>\n            Among 17 included trials, key patient characteristics varied substantially: primary refractory (0\u201369%), refractory to last line of therapy (LOT) (12\u2013100%), \u22652 prior LOTs (14\u2013100%), \u22653 prior LOTs (0\u201364%), IPI \u22653 (23\u201373%), tumor stage III\/IV (50\u201390%) and median age (56\u201374\u00a0years). ORRs varied substantially (25\u201383%), correlating with these characteristics.\n            <jats:bold>Conclusion:<\/jats:bold>\n            Differences in patient characteristics significantly contribute to the variability in ORR across these trials and should be considered when contextualizing efficacy data.\n          <\/jats:p>","DOI":"10.2217\/cer-2022-0146","type":"journal-article","created":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T17:21:18Z","timestamp":1669224078000},"source":"Crossref","is-referenced-by-count":1,"title":["Systematic review of outcomes and patient heterogeneity in relapsed or refractory diffuse large B-cell lymphoma"],"prefix":"10.57264","volume":"12","author":[{"given":"Sally D","family":"Miller","sequence":"first","affiliation":[{"name":"Broadstreet HEOR, 201-343 Railway St,\u00a0Vancouver, BC\u00a0V6A 1A4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Greta","family":"Lozano-Ortega","sequence":"additional","affiliation":[{"name":"Broadstreet HEOR, 201-343 Railway St,\u00a0Vancouver, BC\u00a0V6A 1A4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Mutebi","sequence":"additional","affiliation":[{"name":"Genmab, 777 Scudders Mill Road,\u00a0Plainsboro, NJ 08536, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Owanate","family":"Briggs","sequence":"additional","affiliation":[{"name":"Genmab, 777 Scudders Mill Road,\u00a0Plainsboro, NJ 08536, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kavita","family":"Sail","sequence":"additional","affiliation":[{"name":"AbbVie, 1 N. Waukegan Road,\u00a0Chicago, IL 60064, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Elliott","sequence":"additional","affiliation":[{"name":"Genmab, 777 Scudders Mill Road,\u00a0Plainsboro, NJ 08536, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anupama","family":"Kalsekar","sequence":"additional","affiliation":[{"name":"Genmab, 777 Scudders Mill Road,\u00a0Plainsboro, NJ 08536, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36897","reference":[{"key":"e_1_3_5_3_2","unstructured":"Cancer stat facts: common cancer types. https:\/\/seer.cancer.gov\/statfacts\/ (2022)."},{"issue":"4","key":"e_1_3_5_4_2","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier B","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med.\u00a0346(4), 235\u2013242 (2002).","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"e_1_3_5_5_2","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte","volume":"116","author":"Coiffier B","year":"2010","unstructured":"Coiffier B, Thieblemont C, Van Den Neste E Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood\u00a0116(12), 2040\u20132045 (2010).","journal-title":"Blood"},{"key":"e_1_3_5_6_2","unstructured":"B-Cell Lymphomas (Version 1.2022). www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf (2022)."},{"issue":"5","key":"e_1_3_5_7_2","doi-asserted-by":"crossref","first-page":"v116","DOI":"10.1093\/annonc\/mdv304","article-title":"Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Tilly H","year":"2015","unstructured":"Tilly H, Gomes Da Silva M, Vitolo U Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol.\u00a026(Suppl.\u00a05), v116\u2013v125 (2015).","journal-title":"Ann. Oncol."},{"issue":"7","key":"e_1_3_5_8_2","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1080\/10428194.2018.1564828","article-title":"Treatment of aggressive B-cell non-Hodgkin lymphoma beyond frontline therapy in patients not eligible for stem cell transplantation: a structured review","volume":"60","author":"Salles GA","year":"2019","unstructured":"Salles GA, Pettengell R, Cordoba R, D\u0142ugosz-Danecka M, Jurczak W, Tilly H. Treatment of aggressive B-cell non-Hodgkin lymphoma beyond frontline therapy in patients not eligible for stem cell transplantation: a structured review. Leuk. Lymph.\u00a060(7), 1610\u20131625 (2019).","journal-title":"Leuk. Lymph."},{"issue":"6","key":"e_1_3_5_9_2","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, Phase 2 trial","volume":"22","author":"Caimi PF","year":"2021","unstructured":"Caimi PF, Ai W, Alderuccio JP Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, Phase 2 trial. Lancet Oncol.\u00a022(6), 790\u2013800 (2021).","journal-title":"Lancet Oncol."},{"issue":"10306","key":"e_1_3_5_10_2","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0140-6736(21)00889-8","article-title":"Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1\/2 study","volume":"398","author":"Hutchings M","year":"2021","unstructured":"Hutchings M, Mous R, Clausen MR Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1\/2 study. Lancet\u00a0398(10306), 1157\u20131169 (2021).","journal-title":"Lancet"},{"issue":"12","key":"e_1_3_5_11_2","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.1007\/s12325-020-01507-7","article-title":"A systematic review of the clinical efficacy of treatments in relapsed or refractory diffuse large B cell lymphoma","volume":"37","author":"Thuresson P-O","year":"2020","unstructured":"Thuresson P-O, Vander Velde N, Gupta P, Talbot J. A systematic review of the clinical efficacy of treatments in relapsed or refractory diffuse large B cell lymphoma. Adv. Ther.\u00a037(12), 4877\u2013489 (2020).","journal-title":"Adv. Ther."},{"key":"e_1_3_5_12_2","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JaC","year":"2019","unstructured":"Sterne JaC, Savovi\u0107 J, Page MJ RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ\u00a0366, l4898 (2019).","journal-title":"BMJ"},{"issue":"9","key":"e_1_3_5_13_2","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (minors): development and validation of a new instrument","volume":"73","author":"Slim K","year":"2003","unstructured":"Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J. Surg.\u00a073(9), 712\u2013716 (2003).","journal-title":"ANZ J. Surg."},{"issue":"5","key":"e_1_3_5_14_2","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1213\/ANE.0000000000002864","article-title":"Correlation coefficients: appropriate use and interpretation","volume":"126","author":"Schober P","year":"2018","unstructured":"Schober P, Boer C, Schwarte LA. Correlation coefficients: appropriate use and interpretation. Anesth. Analg.\u00a0126(5), 1763\u20131768 (2018).","journal-title":"Anesth. Analg."},{"issue":"8","key":"e_1_3_5_15_2","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1093\/annonc\/mdm133","article-title":"Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy","volume":"18","author":"El Gnaoui T","year":"2007","unstructured":"El Gnaoui T, Dupuis J, Belhadj K Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Ann. Oncol.\u00a018(8), 1363\u20131368 (2007).","journal-title":"Ann. Oncol."},{"issue":"2","key":"e_1_3_5_16_2","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1600-0609.2007.00996.x","article-title":"GEMOX-R regimen is a highly effective salvage regimen in patients with refractory\/relapsing diffuse large-cell lymphoma: a Phase II study","volume":"80","author":"Lopez A","year":"2008","unstructured":"Lopez A, Gutierrez A, Palacios A GEMOX-R regimen is a highly effective salvage regimen in patients with refractory\/relapsing diffuse large-cell lymphoma: a Phase II study. Eur. J. Haematol.\u00a080(2), 127\u2013132 (2008).","journal-title":"Eur. J. Haematol."},{"issue":"11","key":"e_1_3_5_17_2","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.3324\/haematol.2013.090597","article-title":"Rituximab plus gemcitabine and oxaliplatin in patients with refractory\/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A Phase II Lymphoma Study Association trial","volume":"98","author":"Mounier N","year":"2013","unstructured":"Mounier N, El Gnaoui T, Tilly H Rituximab plus gemcitabine and oxaliplatin in patients with refractory\/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A Phase II Lymphoma Study Association trial. Haematologica\u00a098(11), 1726\u20131731 (2013).","journal-title":"Haematologica"},{"issue":"17","key":"e_1_3_5_18_2","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1200\/JCO.2012.46.5203","article-title":"Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma","volume":"31","author":"Ohmachi K","year":"2013","unstructured":"Ohmachi K, Niitsu N, Uchida T Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. J. Clin. Oncol.\u00a031(17), 2103\u20132109 (2013).","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"e_1_3_5_19_2","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma","volume":"38","author":"Sehn LH","year":"2020","unstructured":"Sehn LH, Herrera AF, Flowers CR Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J. Clin. Oncol.\u00a038(2), 155\u2013165 (2020).","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"e_1_3_5_20_2","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s00277-013-1879-x","article-title":"Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma","volume":"93","author":"Vacirca JL","year":"2014","unstructured":"Vacirca JL, Acs PI, Tabbara IA, Rosen PJ, Lee P, Lynam E. Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma. Ann. Hematol.\u00a093(3), 403\u2013409 (2014).","journal-title":"Ann. Hematol."},{"issue":"7","key":"e_1_3_5_21_2","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1111\/cas.14937","article-title":"A Phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed\/refractory diffuse large B-cell lymphoma","volume":"112","author":"Terui Y","year":"2021","unstructured":"Terui Y, Rai S, Izutsu K A Phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed\/refractory diffuse large B-cell lymphoma. Cancer Sci.\u00a0112(7), 2845\u20132854 (2021).","journal-title":"Cancer Sci."},{"issue":"10254","key":"e_1_3_5_22_2","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson JS","year":"2020","unstructured":"Abramson JS, Palomba ML, Gordon LI Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet\u00a0396(10254), 839\u2013852 (2020).","journal-title":"Lancet"},{"issue":"26","key":"e_1_3_5_23_2","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-Cell lymphoma","volume":"377","author":"Neelapu SS","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-Cell lymphoma. N. Engl. J. Med.\u00a0377(26), 2531\u20132544 (2017).","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"e_1_3_5_24_2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster SJ","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N. Engl. J. Med.\u00a0380(1), 45\u201356 (2019).","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"e_1_3_5_25_2","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","article-title":"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, Phase 2 study","volume":"21","author":"Salles G","year":"2020","unstructured":"Salles G, Duell J, Barca EG Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, Phase 2 study. Lancet Oncol.\u00a021(7), 978\u2013988 (2020).","journal-title":"Lancet Oncol."},{"issue":"7","key":"e_1_3_5_26_2","doi-asserted-by":"crossref","first-page":"e511","DOI":"10.1016\/S2352-3026(20)30120-4","article-title":"Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial","volume":"7","author":"Kalakonda N","year":"2020","unstructured":"Kalakonda N, Maerevoet M, Cavallo F Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol.\u00a07(7), e511\u2013e522 (2020).","journal-title":"Lancet Haematol."},{"issue":"2","key":"e_1_3_5_27_2","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/bjh.16255","article-title":"Pixantrone plus rituximab versus gemcitabine plus rituximab in patients with relapsed aggressive B-cell non-Hodgkin lymphoma not eligible for stem cell transplantation: a phase 3, randomized, multicentre trial (PIX306)","volume":"188","author":"Pettengell R","year":"2020","unstructured":"Pettengell R, Dlugosz-Danecka M, Andorsky D Pixantrone plus rituximab versus gemcitabine plus rituximab in patients with relapsed aggressive B-cell non-Hodgkin lymphoma not eligible for stem cell transplantation: a phase 3, randomized, multicentre trial (PIX306). Brit. J. Haematol.\u00a0188(2), 240\u2013248 (2020).","journal-title":"Brit. J. Haematol."},{"issue":"6","key":"e_1_3_5_28_2","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.clml.2011.02.001","article-title":"Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a Phase 2 trial","volume":"11","author":"Zinzani PL","year":"2011","unstructured":"Zinzani PL, Pellegrini C, Gandolfi L Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a Phase 2 trial. Clin. Lymph. Myeloma Leuk.\u00a011(6), 462\u2013466 (2011).","journal-title":"Clin. Lymph. Myeloma Leuk."},{"issue":"6","key":"e_1_3_5_29_2","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3816\/CLM.2007.n.019","article-title":"Efficacy and safety of rituximab combined with ESHAP chemotherapy for the treatment of relapsed\/refractory aggressive B-cell non-Hodgkin lymphoma","volume":"7","author":"Harting R","year":"2007","unstructured":"Harting R, Venugopal P, Gregory SA, O'Brien T, Bogdanova E. Efficacy and safety of rituximab combined with ESHAP chemotherapy for the treatment of relapsed\/refractory aggressive B-cell non-Hodgkin lymphoma. Clin. Lymph. Myeloma\u00a07(6), 406\u2013412 (2007).","journal-title":"Clin. Lymph. Myeloma"},{"issue":"2","key":"e_1_3_5_30_2","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1600-0609.2005.00482.x","article-title":"Combination chemotherapy with gemcitabine and vinorelbine in the treatment of relapsed or refractory diffuse large B-cell lymphoma: a phase-II trial by the Hellenic Cooperative Oncology Group","volume":"75","author":"Papageorgiou ES","year":"2005","unstructured":"Papageorgiou ES, Tsirigotis P, Dimopoulos M Combination chemotherapy with gemcitabine and vinorelbine in the treatment of relapsed or refractory diffuse large B-cell lymphoma: a phase-II trial by the Hellenic Cooperative Oncology Group. Eur. J. Haematol.\u00a075(2), 124\u2013129 (2005).","journal-title":"Eur. J. Haematol."},{"issue":"1","key":"e_1_3_5_31_2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2020-137078","article-title":"Polatuzumab vedotin plus bendamustine and rituximab in relapsed\/refractory diffuse large B-cell lymphoma: updated results of a phase Ib\/II randomized study and preliminary results of a single-arm extension","volume":"136","author":"Sehn LH","year":"2020","unstructured":"Sehn LH, Hertzberg M, Opat S Polatuzumab vedotin plus bendamustine and rituximab in relapsed\/refractory diffuse large B-cell lymphoma: updated results of a phase Ib\/II randomized study and preliminary results of a single-arm extension. Blood\u00a0136(Suppl.\u00a01), 17\u201319 (2020).","journal-title":"Blood"},{"issue":"4","key":"e_1_3_5_32_2","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson BD","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J. Clin. Oncol.\u00a017(4), 1244 (1999).","journal-title":"J. Clin. Oncol."},{"issue":"27","key":"e_1_3_5_33_2","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson BD","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J. Clin. Oncol.\u00a032(27), 3059\u20133068 (2014).","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"e_1_3_5_34_2","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson BD","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME Revised response criteria for malignant lymphoma. J. Clin. Oncol.\u00a025(5), 579\u2013586 (2007).","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"e_1_3_5_35_2","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1007\/s00277-012-1463-9","article-title":"The impact of age, Charlson comorbidity index, and performance status on treatment of elderly patients with diffuse large B cell lymphoma","volume":"91","author":"Lin TL","year":"2012","unstructured":"Lin TL, Kuo MC, Shih LY The impact of age, Charlson comorbidity index, and performance status on treatment of elderly patients with diffuse large B cell lymphoma. Ann. Hematol.\u00a091(9), 1383\u20131391 (2012).","journal-title":"Ann. Hematol."},{"issue":"16","key":"e_1_3_5_36_2","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump M","year":"2017","unstructured":"Crump M, Neelapu SS, Farooq U Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood\u00a0130(16), 1800\u20131808 (2017).","journal-title":"Blood"},{"issue":"5","key":"e_1_3_5_37_2","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S2352-3026(22)00072-2","article-title":"Odronextamab, a human CD20\u00d7CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial","volume":"9","author":"Bannerji R","year":"2022","unstructured":"Bannerji R, Arnason JE, Advani RH Odronextamab, a human CD20\u00d7CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol.\u00a09(5), e327\u2013e339 (2022).","journal-title":"Lancet Haematol."},{"issue":"16","key":"e_1_3_5_38_2","doi-asserted-by":"crossref","first-page":"7500","DOI":"10.1200\/JCO.2022.40.16_suppl.7500","article-title":"Glofitamab in patients with relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL) and \u22652 prior therapies: pivotal Phase II expansion results","volume":"40","author":"Dickinson M","year":"2022","unstructured":"Dickinson M, Carlo-Stella C, Morschhauser F Glofitamab in patients with relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL) and \u22652 prior therapies: pivotal Phase II expansion results. J. Clin. Oncol.\u00a040(Suppl.\u00a016), 7500\u20137500 (2022).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_5_39_2","volume-title":"The European Hematology Association Congress","author":"Thieblemont C","year":"2022","unstructured":"Thieblemont C, Phillips T, Ghesquieres H Primary results of subcutaneous epcoritamab dose expansion in patients with relapsed or refractory large B-cell lymphoma: a Phase 2 study. Presented at: The European Hematology Association Congress (2022)."},{"key":"e_1_3_5_40_2","unstructured":"National Institute for Health and Care Excellence. Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (TA567). Technology appraisal guidance. Available at: www.nice.org.uk\/guidance\/ta567 (2019)."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.2217\/cer-2022-0146","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,19]],"date-time":"2023-03-19T12:42:44Z","timestamp":1679229764000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.2217\/cer-2022-0146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.2217\/cer-2022-0146"],"URL":"https:\/\/doi.org\/10.2217\/cer-2022-0146","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"type":"print","value":"2042-6305"},{"type":"electronic","value":"2042-6313"}],"subject":[],"published":{"date-parts":[[2023,1]]},"article-number":"cer-2022-0146"}}